These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 30773077)

  • 1. Toxicity and efficacy of alemtuzumab combined with CHOP for aggressive T-cell lymphoma: a phase 1 dose-escalation trial.
    Phillips EH; Devereux S; Radford J; Mir N; Adedayo T; Clifton-Hadley L; Johnson R
    Leuk Lymphoma; 2019 Sep; 60(9):2291-2294. PubMed ID: 30773077
    [No Abstract]   [Full Text] [Related]  

  • 2. Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
    Wunderlich A; Kloess M; Reiser M; Rudolph C; Truemper L; Bittner S; Schmalenberg H; Schmits R; Pfreundschuh M; Loeffler M;
    Ann Oncol; 2003 Jun; 14(6):881-93. PubMed ID: 12796026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy with cyclophosphamide, doxorubicin, etoposide, vincristine and prednisone (CHOEP) is not effective in patients with enteropathy-type intestinal T-cell lymphoma.
    Wöhrer S; Chott A; Drach J; Püspök A; Hejna M; Hoffmann M; Raderer M
    Ann Oncol; 2004 Nov; 15(11):1680-3. PubMed ID: 15520071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
    Robak T; Jin J; Pylypenko H; Verhoef G; Siritanaratkul N; Drach J; Raderer M; Mayer J; Pereira J; Tumyan G; Okamoto R; Nakahara S; Hu P; Appiani C; Nemat S; Cavalli F;
    Lancet Oncol; 2018 Nov; 19(11):1449-1458. PubMed ID: 30348538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-escalation study of CHOP with or without prophylactic G-CSF in aggressive non-Hodgkin's lymphoma.
    Itoh K; Ohtsu T; Wakita H; Igarashi T; Ishizawa K; Onozawa Y; Fujii H; Minami H; Sasaki Y
    Ann Oncol; 2000 Oct; 11(10):1241-7. PubMed ID: 11106111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505.
    Itoh K; Ohtsu T; Fukuda H; Sasaki Y; Ogura M; Morishima Y; Chou T; Aikawa K; Uike N; Mizorogi F; Ohno T; Ikeda S; Sai T; Taniwaki M; Kawano F; Niimi M; Hotta T; Shimoyama M; Tobinai K;
    Ann Oncol; 2002 Sep; 13(9):1347-55. PubMed ID: 12196359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group.
    Peyrade F; Bologna S; Delwail V; Emile JF; Pascal L; Fermé C; Schiano JM; Coiffier B; Corront B; Farhat H; Fruchart C; Ghesquieres H; Macro M; Tilly H; Choufi B; Delarue R; Fitoussi O; Gabarre J; Haioun C; Jardin F
    Lancet Haematol; 2017 Jan; 4(1):e46-e55. PubMed ID: 28041583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of the Incidence of Infections and Acute Biochemical Changes in Diffused Large B-Cell Lymphoma Patients Treated with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (CHOP) with and without Rituximab.
    Ali K; Sial AA; Baig MT; Ansari SH; Adil SO; Shamsi TS
    Curr Drug Saf; 2018; 13(2):102-106. PubMed ID: 29564988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of interstitial pneumonitis in non-Hodgkin's lymphoma patients receiving immunochemotherapy with pegylated liposomal doxorubicin and rituximab.
    Zhou T; Shen Q; Peng H; Chao T; Zhang L; Huang L; Yang K; Thapa S; Yu S; Jiang Y
    Ann Hematol; 2018 Jan; 97(1):141-147. PubMed ID: 29086009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical randomized comparative trial of ProMACE-CytaBOM regimen and CHOP regimen in treating non-Hodgkin's lymphoma].
    Hou M; Li L; Qiu M; Yan X; Zhu J; Gou HF
    Ai Zheng; 2005 Apr; 24(4):461-4. PubMed ID: 15820070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
    Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
    Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of the dexamethasone, cytarabine, and cisplatin (DHAP) regimen on stem cell mobilization and transplant outcomes of patients with non-Hodgkin's lymphoma who are candidates for up-front autologous stem cell transplantation.
    Jeon SY; Yhim HY; Kim HS; Kim JA; Yang DH; Kwak JY
    Korean J Intern Med; 2018 Nov; 33(6):1169-1181. PubMed ID: 29295612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety.
    Hiddemann W; Barbui AM; Canales MA; Cannell PK; Collins GP; Dürig J; Forstpointner R; Herold M; Hertzberg M; Klanova M; Radford J; Seymour JF; Tobinai K; Trotman J; Burciu A; Fingerle-Rowson G; Wolbers M; Nielsen T; Marcus RE
    J Clin Oncol; 2018 Aug; 36(23):2395-2404. PubMed ID: 29856692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perianal tuberculosis during neutropenia: a rare case report and review of literature.
    Lin CY; Yeh SP; Huang HH; Liao YM; Chiu CF
    Ann Hematol; 2006 Aug; 85(8):547-8. PubMed ID: 16572324
    [No Abstract]   [Full Text] [Related]  

  • 15. Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2.
    Godfrey JK; Nabhan C; Karrison T; Kline JP; Cohen KS; Bishop MR; Stadler WM; Karmali R; Venugopal P; Rapoport AP; Smith SM
    Cancer; 2019 Jun; 125(11):1830-1836. PubMed ID: 30707764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term results of a multicenter randomized, comparative trial of modified CHOP versus THP-COP versus THP-COPE regimens in elderly patients with non-Hodgkin's lymphoma.
    Mori M; Kitamura K; Masuda M; Hotta T; Miyazaki T; Miura AB; Mizoguchi H; Shibata A; Saito H; Matsuda T; Masaoka T; Harada M; Niho Y; Takaku F
    Int J Hematol; 2005 Apr; 81(3):246-54. PubMed ID: 15814336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pilot study of modified version of CHOP plus radiotherapy for early-stage aggressive non-Hodgkin's lymphoma of the head and neck.
    Nishioka T; Tsuchiya K; Nishioka S; Kitahara T; Ohmori K; Homma A; Aoyma H; Shindoh M; Shirato H
    Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):847-52. PubMed ID: 15465202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relative dose intensity of R-CHOP therapy and patient outcomes in advanced follicular lymphoma.
    Konishi T; Kanemasa Y; Sasaki Y; Okuya T; Yamaguchi T; Funasaka C; Shimoyama T; Omuro Y
    Hematol Oncol; 2019 Aug; 37(3):303-307. PubMed ID: 30933366
    [No Abstract]   [Full Text] [Related]  

  • 19. Oral CHOP-like chemotherapy in 60-80 years-old patients with diffuse large B-cell lymphoma.
    Guidez S; Lacotte-Thierry L; Tomowiak C; Princet I; Dreyfus B; Olivier G; Fleck E; Corby A; Motard C; Barrier J; Machet A; Le Dû K; Debiais-Delpech C; Chabin M; Leleu X; Guilhot J; Delwail V
    Br J Haematol; 2019 Sep; 186(6):e175-e178. PubMed ID: 31309541
    [No Abstract]   [Full Text] [Related]  

  • 20. [Long-term results with MACOP-B and radiation therapy for aggressive lymphomas].
    Krieger G; Kreysing E; Kneba M
    Onkologie; 2001 Feb; 24 Suppl 1():49-58. PubMed ID: 11441311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.